Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.
Chardan Capital analyst Daniil Gataulin maintains Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $11 price target.
HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.19) per share which met the analyst consensus estimate. This is a...
HC Wainwright & Co. analyst Emily Bodnar reiterates Purple Biotech (NASDAQ:PPBT) with a Buy and maintains $10 price target.
NT219 is a first-in-class small molecule dual inhibitor of IRS1/2 and STAT3. The Phase 1 dose escalation study is being conclud...
